{"id":501089,"date":"2020-08-07T19:56:01","date_gmt":"2020-08-07T19:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=501089"},"modified":"2020-08-07T19:56:01","modified_gmt":"2020-08-07T19:56:01","slug":"lag3next-generation-immunotherapy-competitive-landscape-and-market-forecast-2035","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lag3next-generation-immunotherapy-competitive-landscape-and-market-forecast-2035_501089.html","title":{"rendered":"LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035\u2019 report delivers an in-depth understanding of the LAG-3 as well as the market trends of LAG-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/div>\n<ul style=\"text-align: justify;\">\n<li>Cancer Immunotherapy involves antibodies to inhibit immune checkpoint molecules. Fighting cancer with immunotherapy has revolutionized treatment for some patients and therapies targeting the immune checkpoint molecules such as CTLA-4 and PD-1 in melanoma, renal cancer, Hodgkin&rsquo;s diseases and lung cancer.<\/li>\n<li>Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation, and growth.<\/li>\n<li>T cells are a type of white blood cells that are a part of the immune system. Activation of cytotoxic T cells by antigens enables them to kill unhealthy or foreign cells. It binds MHCII molecules and modulates T-cell function than either CTLA-4 or PD-1.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/LAG-3-next-generation-immunotherapy-competitive-landscape\" target=\"_blank\"><strong>LAG-3-Next Generation Immunotherapy Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">LAG-3-Next Generation Immunotherapy Market is expected to generate USD 3,421 Million by 2035.<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/LAG-3-next-generation-immunotherapy-competitive-landscape\" target=\"_blank\">LAG-3-Next Generation Immunotherapy Market Drivers-<\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li>The launch of potential upcoming therapies in the LAG-3 target during the forecast period (2022&ndash;2035).<\/li>\n<li>Addition of personalized drug therapies with combinational therapies to enhance the efficacy<\/li>\n<li>Increasing funding for R&amp;D expense<\/li>\n<li>A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/LAG-3-next-generation-immunotherapy-competitive-landscape\" target=\"_blank\">LAG-3-Next Generation Immunotherapy Pipeline<\/a><\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>MGD013: MacroGenics\/Zai Lab<\/li>\n<li>MBG453: Novartis<\/li>\n<li>Relatlimab: Bristol-Myers Squibb\/Ono Pharmaceuticals<\/li>\n<li>Eftilagimod Alpha (IMP321): Immutep<\/li>\n<li>LAG525: Novartis<\/li>\n<li>MK-4280: Merck<\/li>\n<li>REGN3767: Regeneron<\/li>\n<li>FS118: F-star Therapeutics<\/li>\n<li>XmAb22841: Xencor<\/li>\n<li>INCAGN2385: Incyte Biosciences\/Agenus<\/li>\n<li>RO7247669: Roche<\/li>\n<li>TSR-033: GlaxoSmithKline<\/li>\n<li>IBI110: Innovent Biologics (Suzhou) Co. Ltd.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">And many others<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lag-3-next-generation-immunotherapy-competitive-landscape\" target=\"_blank\">Request for sample pages<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<h2 style=\"text-align: justify;\">Scope of the report<\/h2>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">&bull; The report covers the descriptive overview of LAG-3-Next Generation Immunotherapy, explaining its pathophysiology, and current trends in the research.<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">&bull; Additionally, an all-inclusive account of emerging therapies for LAG-3-Next Generation Immunotherapy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">&bull; A detailed review of LAG-3-Next Generation Immunotherapy market; historical and forecasted is included in the report, covering drug outreach in the 7MM.<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">&bull; The report provides an edge while developing business strategies, by understanding trends shaping and driving the LAG-3-Next Generation Immunotherapy market.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lag-3-next-generation-immunotherapy-competitive-landscape\" target=\"_blank\">Table of contents<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intensity of LAG-3-Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">4. Market Competition of LAG-3-Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">5. Technological innovations in LAG-3-Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">6. Multivariate analysis of the key players in LAG-3-Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">7. LAG-3-Next Generation Immunotherapy Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">7.1. Market Share (%) Distribution of Next-Generation Immunotherapy in 2035<\/p>\n<p style=\"text-align: justify;\">8. Pipeline Therapeutics Analysis (Active Products)<\/p>\n<p style=\"text-align: justify;\">9. Overview: Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">9.1. Immune Checkpoint Inhibitors<\/p>\n<p style=\"text-align: justify;\">9.2. LAG-3<\/p>\n<p style=\"text-align: justify;\">10. Future Prospects and Challenges in LAG-3-Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">10.1. Current Clinical Challenges in Immunotherapies<\/p>\n<p style=\"text-align: justify;\">10.2. Future direction of improving response rates of Immunotherapy<\/p>\n<p style=\"text-align: justify;\">11. SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">12. Epidemiology and Forecasting Assumptions<\/p>\n<p style=\"text-align: justify;\">13. Emerging Drugs<\/p>\n<p style=\"text-align: justify;\">13.1. Target indications of LAG-3<\/p>\n<p style=\"text-align: justify;\">13.2. MGD013: MacroGenics\/Zai Lab<\/p>\n<p style=\"text-align: justify;\">13.2.1. Drug Description<\/p>\n<p style=\"text-align: justify;\">13.2.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.2.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.2.4. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.3. MBG453: Novartis<\/p>\n<p style=\"text-align: justify;\">13.3.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.3.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.3.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.3.4. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.4. Relatlimab: Bristol-Myers Squibb\/Ono Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">13.4.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.4.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.4.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.4.4. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.5. Eftilagimod Alpha (IMP321): Immutep<\/p>\n<p style=\"text-align: justify;\">13.5.1. Drug Description<\/p>\n<p style=\"text-align: justify;\">13.5.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.5.3. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.6. LAG525: Novartis<\/p>\n<p style=\"text-align: justify;\">13.6.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.6.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.6.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.6.4. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.7. MK-4280: Merck<\/p>\n<p style=\"text-align: justify;\">13.7.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.7.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.7.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.7.4. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.8. REGN3767: Regeneron<\/p>\n<p style=\"text-align: justify;\">13.8.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.8.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.8.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.8.4. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.9. FS118: F-star Therapeutics<\/p>\n<p style=\"text-align: justify;\">13.9.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.9.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.9.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.9.4. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.10. XmAb22841: Xencor<\/p>\n<p style=\"text-align: justify;\">13.10.1.&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.10.2.&nbsp;Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.10.3.&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.10.4.&nbsp;Product Profile<\/p>\n<p style=\"text-align: justify;\">13.11. INCAGN2385: Incyte Biosciences\/Agenus<\/p>\n<p style=\"text-align: justify;\">13.11.1.&nbsp;&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.11.2.&nbsp;&nbsp;Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.11.3.&nbsp;&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.11.4.&nbsp;&nbsp;Product Profile<\/p>\n<p style=\"text-align: justify;\">13.12. RO7247669: Roche<\/p>\n<p style=\"text-align: justify;\">13.12.1.&nbsp;&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.12.2.&nbsp;&nbsp;Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.12.3.&nbsp;&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.12.4.&nbsp;&nbsp;Product Profile<\/p>\n<p style=\"text-align: justify;\">13.13. TSR-033: GlaxoSmithKline<\/p>\n<p style=\"text-align: justify;\">13.13.1.&nbsp;&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.13.2.&nbsp;&nbsp;Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.13.3.&nbsp;&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.13.4.&nbsp;&nbsp;Product Profile<\/p>\n<p style=\"text-align: justify;\">13.14. IBI110: Innovent Biologics (Suzhou) Co. Ltd.<\/p>\n<p style=\"text-align: justify;\">13.14.1.&nbsp;&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.14.2.&nbsp;&nbsp;Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.14.3.&nbsp;&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.14.4.&nbsp;&nbsp;Product Profile<\/p>\n<p style=\"text-align: justify;\">14. Assessment by Indication<\/p>\n<p style=\"text-align: justify;\">15. Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">16. Assessment by Stage and Indication<\/p>\n<p style=\"text-align: justify;\">17. Assessment by stage and Route of Administration<\/p>\n<p style=\"text-align: justify;\">18. LAG-3-7 Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">18.1. Market Outlook in the 7MM<\/p>\n<p style=\"text-align: justify;\">18.1.1. Total Market size of LAG-3 in 7MM<\/p>\n<p style=\"text-align: justify;\">18.1.2. Market Size of LAG-3 by indication in 7MM<\/p>\n<p style=\"text-align: justify;\">19. Market Drivers<\/p>\n<p style=\"text-align: justify;\">20. Market Barriers<\/p>\n<p style=\"text-align: justify;\">21. Appendix<\/p>\n<p style=\"text-align: justify;\">21.1. Report Methodology<\/p>\n<p style=\"text-align: justify;\">22. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">23. Disclaimer<\/p>\n<p style=\"text-align: justify;\">24. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=lag3next-generation-immunotherapy-competitive-landscape-and-market-forecast-2035\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=lag3next-generation-immunotherapy-competitive-landscape-and-market-forecast-2035\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035\u2019 report delivers an in-depth understanding of the LAG-3 as well as the market trends of LAG-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/lag3next-generation-immunotherapy-competitive-landscape-and-market-forecast-2035_501089.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-501089","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=501089"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501089\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=501089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=501089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=501089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}